BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 36959422)

  • 21. Reproducible imaging-based prediction of molecular subtype and risk stratification of gliomas across different experience levels using a structured reporting system.
    Nam YK; Park JE; Park SY; Lee M; Kim M; Nam SJ; Kim HS
    Eur Radiol; 2021 Oct; 31(10):7374-7385. PubMed ID: 34374800
    [TBL] [Abstract][Full Text] [Related]  

  • 22. RNA editing-based classification of diffuse gliomas: predicting isocitrate dehydrogenase mutation and chromosome 1p/19q codeletion.
    Chen SC; Lo CM; Wang SH; Su EC
    BMC Bioinformatics; 2019 Dec; 20(Suppl 19):659. PubMed ID: 31870275
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic role of mitochondrial pyruvate carrier in isocitrate dehydrogenase-mutant glioma.
    Karsy M; Guan J; Huang LE
    J Neurosurg; 2018 Mar; 130(1):56-66. PubMed ID: 29547090
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular classification of adult diffuse gliomas: conflicting IDH1/IDH2, ATRX, and 1p/19q results.
    Ballester LY; Huse JT; Tang G; Fuller GN
    Hum Pathol; 2017 Nov; 69():15-22. PubMed ID: 28549927
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Financially effective test algorithm to identify an aggressive, EGFR-amplified variant of IDH-wildtype, lower-grade diffuse glioma.
    Bale TA; Jordan JT; Rapalino O; Ramamurthy N; Jessop N; DeWitt JC; Nardi V; Alvarez MM; Frosch M; Batchelor TT; Louis DN; Iafrate AJ; Cahill DP; Lennerz JK
    Neuro Oncol; 2019 May; 21(5):596-605. PubMed ID: 30496526
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relevance of calcification and contrast enhancement pattern for molecular diagnosis and survival prediction of gliomas based on the 2016 World Health Organization Classification.
    Michiwaki Y; Hata N; Mizoguchi M; Hiwatashi A; Kuga D; Hatae R; Akagi Y; Amemiya T; Fujioka Y; Togao O; Suzuki SO; Yoshimoto K; Iwaki T; Iihara K
    Clin Neurol Neurosurg; 2019 Dec; 187():105556. PubMed ID: 31639630
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Diagnostic Value of Conventional MRI and CT Features in the Identification of the IDH1-Mutant and 1p/19q Co-Deletion in WHO Grade II Gliomas.
    Zhao K; Sun G; Wang Q; Xue Z; Liu G; Xia Y; Yao A; Zhao Y; You N; Yang C; Xu B
    Acad Radiol; 2021 Jul; 28(7):e189-e198. PubMed ID: 32359929
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multicentric Registry Study on Epidemiological and Biological Disease Profile as Well as Clinical Outcome in Patients with Low-Grade Gliomas: The LoG-Glio Project.
    Pala A; Nadji-Ohl M; Faust K; Rückriegel S; Roder C; von der Brelie C; Forster MT; Löbel F; Schommer S; Löhr M; Renovanz M; Grübel N; Rothenbacher D; König R; Engelke J; Schmitz B; Wirtz CR; Ringel F; Senft C; Rohde V; Tatagiba M; Ernestus RI; Vajkoczy P; Ganslandt O; Nagel G; Coburger J
    J Neurol Surg A Cent Eur Neurosurg; 2020 Jan; 81(1):48-57. PubMed ID: 31550737
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunohistochemistry on IDH 1/2, ATRX, p53 and Ki-67 substitute molecular genetic testing and predict patient prognosis in grade III adult diffuse gliomas.
    Takano S; Ishikawa E; Sakamoto N; Matsuda M; Akutsu H; Noguchi M; Kato Y; Yamamoto T; Matsumura A
    Brain Tumor Pathol; 2016 Apr; 33(2):107-16. PubMed ID: 26968173
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Imaging-Based Versus Pathologic Survival Stratifications of Diffuse Glioma According to the 2021 WHO Classification System.
    Lee SJ; Park JE; Park SY; Kim YH; Hong CK; Kim JH; Kim HS
    Korean J Radiol; 2023 Aug; 24(8):772-783. PubMed ID: 37500578
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnostic Performance of [
    Nakajo K; Uda T; Kawashima T; Terakawa Y; Ishibashi K; Tsuyuguchi N; Tanoue Y; Nagahama A; Uda H; Koh S; Sasaki T; Ohata K; Kanemura Y; Goto T
    World Neurosurg; 2021 Apr; 148():e471-e481. PubMed ID: 33444827
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IDH mutations in older patients with diffuse astrocytic gliomas.
    Andrews C; Prayson RA
    Ann Diagn Pathol; 2020 Dec; 49():151653. PubMed ID: 33137656
    [TBL] [Abstract][Full Text] [Related]  

  • 33. TERT promoter mutations contribute to IDH mutations in predicting differential responses to adjuvant therapies in WHO grade II and III diffuse gliomas.
    Zhang ZY; Chan AK; Ding XJ; Qin ZY; Hong CS; Chen LC; Zhang X; Zhao FP; Wang Y; Wang Y; Zhou LF; Zhuang Z; Ng HK; Yan H; Yao Y; Mao Y
    Oncotarget; 2015 Sep; 6(28):24871-83. PubMed ID: 26314843
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diffuse Gliomas for Nonneuropathologists: The New Integrated Molecular Diagnostics.
    Lee SC
    Arch Pathol Lab Med; 2018 Jul; 142(7):804-814. PubMed ID: 29775073
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diffuse gliomas in patients aged 55 years or over: A suggestion for IDH mutation testing.
    Barresi V; Eccher A; Simbolo M; Cappellini R; Ricciardi GK; Calabria F; Cancedda M; Mazzarotto R; Bonetti B; Pinna G; Sala F; Ghimenton C; Scarpa A
    Neuropathology; 2020 Feb; 40(1):68-74. PubMed ID: 31758617
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impending Impact of Molecular Pathology on Classifying Adult Diffuse Gliomas.
    Macaulay RJ
    Cancer Control; 2015 Apr; 22(2):200-5. PubMed ID: 26068765
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Integration of dynamic parameters in the analysis of
    Ginet M; Zaragori T; Marie PY; Roch V; Gauchotte G; Rech F; Blonski M; Lamiral Z; Taillandier L; Imbert L; Verger A
    Eur J Nucl Med Mol Imaging; 2020 Jun; 47(6):1381-1390. PubMed ID: 31529264
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular genetics of adult grade II gliomas: towards a comprehensive tumor classification system.
    Figarella-Branger D; Bouvier C; de Paula AM; Mokhtari K; Colin C; Loundou A; Chinot O; Metellus P
    J Neurooncol; 2012 Nov; 110(2):205-13. PubMed ID: 22890969
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel fully automated MRI-based deep-learning method for classification of IDH mutation status in brain gliomas.
    Bangalore Yogananda CG; Shah BR; Vejdani-Jahromi M; Nalawade SS; Murugesan GK; Yu FF; Pinho MC; Wagner BC; Mickey B; Patel TR; Fei B; Madhuranthakam AJ; Maldjian JA
    Neuro Oncol; 2020 Mar; 22(3):402-411. PubMed ID: 31637430
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of dynamic susceptibility magnetic resonance imaging at initial tumor diagnosis with the prognosis of different molecular glioma subtypes.
    Brendle C; Klose U; Hempel JM; Schittenhelm J; Skardelly M; Tabatabai G; Ernemann U; Bender B
    Neurol Sci; 2020 Dec; 41(12):3625-3632. PubMed ID: 32462389
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.